In this study we have evaluated the in vitro effects of four different aminobisphosphonates, alendronate, risedronate, neridronate and zoledronate, on Vγ9Vδ2 T cell activation and differentiation. All tested aminobisphosphonates induce an IL-2-dependent activation and expansion of Vγ9Vδ2 T lymphocytes in primary PBMC cultures of healthy donors. Most notably, they also determine a different distribution of Vγ9Vδ2 T cell subsets, with decrease of Tnaive and TCM cells and increase of TEM and TEMRA Vγ9Vδ2 cells, indicating that in vitro treatment with aminobisphosphonates induces Vγ9Vδ2 T lymphocytes to differentiate towards an effector/cytotoxic phenotype. Accordingly, Vγ9Vδ2 T lymphocytes cultured with aminobisphosphonates and IL-2 showed a major content of IFN-γ and acquired the ability to kill tumor target cells.
SatoM.GrasserW.EndoN.AkinsR.SimmonsH.ThompsonD.D.GolubE.RodanG.A., 1991. Bisphosphonates action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest.88:2095.
2.
BillerS.A.ForsterC.GordonE.M.HarrityT.ScottW.A.CiosekC.P.Jr, 1988. Isoprenoid (phosphinylmethyl) phosphonates as inhibitors of squalene synthetase. J. Med. Chem.31:1869.
3.
AminD.CornellS.A.GustafsonS.K.NeedleS.J.UllrichJ.W.BilderG.E.PerroneM.H., 1992. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid. Res.33:1657.
4.
CiosekC.P.Jr.MagninD.R.HarrityT.W.LoganJ.V.DicksonJ.K.Jr.GordonE.M.HamiltonK.A.JoliboisK.G.KunselmanL.K.LawrenceR.M., 1993. Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem.268:24832.
5.
AminD.CornellS.A.PerroneM.H.BilderG.E., 1996. 1-Hydroxy-3-(methylpenthylamino)-propylidene-1,1-bisphosphonic acid as a potent inibitor of squalene synthase. Arzneimittelforschung46:759.
6.
FrolikC.A.BryantH.U.BlackE.C.MageeD.E.ChandrasekharS., 1996. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HC1, tamoxifen, estrogen, and alendronate. Bone18:621.
7.
BergstromJ.D.BostedorR.G.MasarachiaP.J.ReszkaA.A.RodanG., 2000. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys.373:231.
8.
van BeekE.PietermanE.CohenL.LowikC.PapapoulosS., 1999. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun.255:491.
9.
van BeekE.PietermanE.CohenL.LowikC.PapapoulosS., 1999. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun.264:108.
10.
DunfordJ.E.ThompsonK.CoxonF.P.LuckmanS.P.HahnF.M.PoulterC.D.EbetinoF.H.RogersM.J., 2001. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther.296:235.
11.
MartinM.B.ArnoldW.HeathH.T.UrbinaJ.A.OldfieldE., 1999. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem. Biophys. Res. Commun.263:754.
12.
EbetinoF.H.RogersM.J.DunfordJ.E., 2002. Modeling of bisphosphonate binding to farnesyl diphosphate synthase. Bone30(S):40.
13.
DunfordJ.E.EbetinoF.H.RogersM.J., 2002. The mechanism of inhibition of farnesyl diphosphate synthase by nitrogen-containing bisphosphonates. Bone30(S):40.
14.
ZhangF.L.CaseyP.J., 1996. Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem.65:241.
15.
SinenskyM.2000. Recent advances in the study of prenylated proteins. Biochem. Biophys. Acta1484:93.
16.
LuckmanS.P.HughesD.E.CoxonF.P.GrahamR.RussellG.RogersM.J., 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res.13:581.
17.
ReszkaA.RodanG., 2003. Bisphosphonate mechanism of action. Curr. Rheum. Reports5:65.
18.
CoxonF.P.HelfrichM.H.LarijaniB.MuzylakM.DunfordJ.E.MarshallD.McKinnonA.D.NesbittS.A.HortonM.A.SeabraM.C.EbetinoF.H.RogersM.J., 2001. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J. Biol. Chem.276:48213.
19.
van BeekE.LowikC.W.EbetinoF.H.PapapoulosS.E., 1998. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone23:437.
20.
RidleyA.J.HalA., 1992. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell70:389.
21.
RidleyA.J.PatersonH.S.JohnstonC.L.DiekmannD.HallA., 1992. The small GTP-binding protein rac regulates growth factor- induced membrane ruffling. Cell70:401.
22.
ZhangD.UdagawaN.NakamuraI.MurakamiH.SaitoS.YamasakiK.ShibasakiY.MoriiN.NarumiyaS.TakahashiN., 1995. The small GTP-binding protein rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J. Cell. Sci.108:2285.
23.
ClarkE.A.KingW.G.BruggeJ.S.SymonsM.HynesR.O., 1998. Integrin-mediated signals regulated by members of the rho family of GTPases. J. Cell. Biol.142:573.
24.
KunzmannV.BauerE.FeurleJ.WeissingerF.TonyH.P.WilhelmM., 2000. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood96:384.
25.
DavidP.NguyenH.BarbierA.R.BaronR., 1996. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J. Bone Miner. Res.11:1498.
26.
FrithJ.C.MonkkonenJ.AuriolaS.MonkkonenH.RogersM.J., 2001. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rrheum. 44:2201.
27.
DieliF.GebbiaN.PocciaF.CaccamoN.MontesanoC.FulfaroF.ArcaraC.ValerioM.R.MeravigliaS.Di SanoC.SireciG.SalernoA., 2003. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood102:2310.
28.
GoberH.J.KistowskaM.AngmanL.JenoP.MoriL.De LiberoG., 2003. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med.197:163.
29.
MiyagawaF.TanakaY.YamashitaS.MinatoN., 2001. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J. Immunol.166:5508.
30.
MoritaC.T.BeckmanE.M.BukowskiJ.F.TanakaY.BandH.BloomB.R.GolanD.E.BrennerM.B., 1995. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity4:495.
31.
GioiaC.AgratiC.CasettiR.CairoC.BorsellinoG.BattistiniL.MancinoG.GolettiD.ColizziV.PucilloL.P.PocciaF., 2002. Lack of CD27CD45RA− Vγ9Vδ2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J. Immunol.168:1484.
32.
DieliF.PocciaF.LippM.SireciG.CaccamoN.Di SanoC.SalernoA., 2003. Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med.198:391.
33.
WilhelmM.KunzmannV.EcksteinS.ReimerP.WeissingerF.RuedigerT.TonyH.P., 2003. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood102:200.
FischP.MalkovskyM.KovatsS.SturmE.BraakmanE.KleinB.S.VossS.D.MorrisseyL.W.DeMarsR.WelchW.J., 1990. Recognition by human Vγ9Vδ2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science250:1269.
36.
FrithJ.C.MonkkonenJ.BlackburnG.M.RussellR.G.RogersM.J., 1997. Clodronate and liposome-encapsulated clodronate are metabolised to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res.12:1358.
37.
FisherJ.E.RogersM.J.HalasyJ.M.LuckmanS.P.HughesD.E.MasarachiaP.J.WesolowskiG.RussellR.G.RodanG.A.ReszkaA.A., 1999. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA96:133.
38.
SandersJ.M.GhoshS.ChanJ.M.MeintsG.WangH.RakerA.M.SongY.ColantinoA.BurzynskaA.KafarskiP.MoritaC.T.OldfieldE., 2004. Quantitative structure-activity relationships for gamma/delta T cell activation by bisphosphonates. J. Med. Chem.47:375.
39.
SalernoA.DieliF., 1998. Role of γδ T lymphocytes in immune responses in humans and mice. Crit. Rev. Immunol.18:327.
40.
DieliF.Troye-BlombergM.IvanyiJ.FournieJ.J.BonnevilleM.PeyratM.A.SireciG.SalernoA., 2000. Vγ9/Vδ2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur. J. Immunol.30:1512.
41.
DieliF.Troye-BlombergM.IvanyiJ.FournieJ.J.KrenskyA.M.BonnevilleM.PeyratM.A.CaccamoN.SireciG.SalernoA., 2001. Granulisyn-depent killing of intracellular and extracellular Mycobacterium tuberculosis by Vγ9/Vδ2 T lymphocytesJ. Infect. Dis.184:1082.
42.
LanzavecchiaA.SallustoF., 2002. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol.2:982.
43.
HewittR.E.LissinaA.GreenA.E.SlayE.S.PriceD.A.SewellA.K., 2005. The bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol.139:101.
44.
ThompsonK.RogersM.J., 2004. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J. Bone Miner. Res.19:278.
45.
CaccamoN.MeravigliaS.FerlazzoV.AngeliniD.BorsellinoG.PocciaF.BattistiniL.DieliF.SalernoA., 2005. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur. J. Immunol.35:1764.
46.
KabelitzD.WeschD.PittersE.ZollerM., 2004. Characterization of tumor reactivity of human Vgamma9Vdelta2 gamma delta T cells in vitro and in SCID mice in vivo. J. Immunol.173:6767.
